Preliminary Clinical Study of NMN Intervention in Mild Ulcerative Colitis

Launched by THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY · Jan 10, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called nicotinamide mononucleotide (NMN) to see if it can help reduce the symptoms of mild ulcerative colitis (UC), a condition that causes inflammation in the lining of the intestines. The study will compare the effects of NMN with a placebo (a treatment that looks like the real thing but has no active ingredients) over 8 weeks. Researchers want to find out if NMN can improve the health of the intestines in people with this condition.

To participate, individuals need to be between 18 and 75 years old and have a clinical diagnosis of mild active ulcerative colitis. However, certain people will not be eligible, including those with severe liver or kidney problems, certain infections, or other serious health issues. Participants will be randomly assigned to either receive NMN or the placebo, and they will be monitored throughout the study. This trial is currently recruiting participants, and those interested should discuss it with their healthcare provider to see if they qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years old, ≤75 years old;
• • 2. Clinical diagnosis of mild active UC patients, the diagnosis standard reference inflammatory bowel disease diagnosis and treatment of the consensus of opinion 2018.
• • 3. Agreed to participate in this study, and sign the informed consent.
• Exclusion Criteria:
• • 1. Patients with ALT or AST more than 2 times the upper limit of normal, TBIL more than 2 times the upper limit of normal;
• • 2. The creatinine clearance patients less than 60 ml/min.
• • 3. The intestines or other parts have severely active infection patients need to use antibiotics or antiviral drugs;
• • 4. Crohn's disease and intestinal tuberculosis and other chronic intestinal infectious disease, intestinal malignant tumor patients;
• • 5. Pregnancy and lactation women;
• • 6. People with diabetes or screening period more than 7.0 tendency for fasting glucose/L or glycosylated hemoglobin exceed 6.5%;
• • 7. With serious mental illness, such as drugs and alcohol can't cooperate with the patients;
• • 8. Participated in any other clinical investigator within 1 month before the screening period;
• • 9. The researchers determine any other disease or condition is not suitable for patients participate in the study.